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Abstract 
 
Extra-gonadal germ cell tumours (EGGCT) are rare. Therefore further investigations of the testis is aimed at 
sourcing a possible primary origin of gonadal tumour. Over the years, various case series on EGGCT have been 
reported questioning its true nature as in a majority of them, a primary source is found in the testis, thus representing 
a metastatic gonadal tumour. The testis pathology could be either a true germ cell foci, an intra-tubular epithelial 
neoplasia or an area of fibrosis, indicating a „burnt out tumour‟. We report a 39-year-old male who underwent 
laparotomy and excision of a retroperitoneal tumour.  Histopathological examination revealed retroperitoneal lymph 
node of mixed germ cell tumour origin. Clinical and ultrasound examination of bilateral testis was normal. The 
patient refused orchidectomy or a testicular biopsy. He underwent four cycles of bleomycin, cisplatin, and etoposide 
with no evidence of tumour recurrence on follow up and remains disease free after 12 months of diagnosis. A 
literature review of EGGCT, its relation and factors relating with future testicular tumour is presented.  
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Introduction 
 
Extra-gonadal germ cell tumour (EGGCT) is a rare 
entity. Many researchers have questioned its true 
existence as a primary testicular lesions are often 
found via thorough investigations in cases presumed 
EGGCT. Controversies regarding subsequent 
management of the testis in cases of EGGCT are on-
going as there are no clear set guidelines. Here, we 
report a case of a young man with EGGCT and look 
into literature with regards to current methods of the 
testis and follow up periods. 
 
Case report  
 
A 42-year-old man presented with lassitude for 1 
month associated with low grade fever and 
intermittent back pain. He complained of loss of 
appetite for 3 weeks without obvious loss of weight.  
 
 
Physical examination of the abdomen was 
unremarkable and there were no abnormalities of the 
external genitalia.  A biochemical test offered by a 
private laboratory which included tumour markers 
revealed that his alpha-feto protein levels was 3238 
ng/ml (0- 6.67ng/ml)  beta-human chorionic 
gonadotropin was less than 1.2mIU/ml. Computed 
tomography (CT) scan revealed a mass in the 
retroperitoneum within the para-aortic region (Fig 1). 
 
The patient underwent laparotomy and excision of the 
retroperitoneal mass. Gross inspection of the mass 
resembled an enlarged para-aortic lymph node which 
was situated on the left side of the retroperitoneum. 
No other lymphadenopathy was present elsewhere. 
Macroscopic examination revealed a lobulated firm 
mass measuring 5.5 X 3.5 X 3.0 cm. Cut section 
showed a solid homogenous greyish area with areas 
of necrosis. Microscopically, the mass composed of 
lymphoid tissue extensively replaced by malignant 
cells. Immunohistochemistry studies showed that the 
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tumour cells were positive for alpha-feto protein. 
Thus it was concluded that this lymph node 
represented a metastatic mixed germ cell tumour 
(yolk sac and embryonal carcinoma). 
 
Ultrasound revealed normal echo pattern of bilateral 
testis. No focal lesions were seen. The right testis 
measured 2.6 X 3.6, while left testis measured 2.8 X 
3.6cm. With the diagnosis of extra-gonadal germ cell 
tumour, the patient underwent 4 cycles of 
chemotherapy with each 3-week cycle consisting of 
bleomycin, cisplatin, and etoposide. Five months 
following chemotherapy CT abdomen revealed no 
residual tumour. The alpha-feto protein levels reduced 
on follow up (from 263 to 5.8ng/ml). He was 
counselled for a testicular biopsy but opted for regular 
surveillance instead. He remains tumour free 12 
months after diagnosis.  
 
 
 
 
 
 
 
Discussion 
 
Extra-gonadal germ cell tumours (EGGCT) are a rare 
entity. It represents 5-10% of all germ cell tumours 
(1). They have a predilection to occur along midline 
structures such as the retroperitoneum, pineal gland 
and mediatsinum. True EGGCT are difficult to 
ascertain unless we exclude a primary source from the 
testis. An assumed EGGCT may actually represent a 
metastatic tumour from an indolent or clinically 
undetected primary germ cell tumour of the testis.  
 
There are two possible reasons for this occurrence. In 
one situation, the testis may harbour an occult tumour 
that has metastasized but it is normal on clinical 
examination. However an ultrasound examination 
may reveal a small testicular lesion. This would then 
be confirmed by a testicular biopsy or an 
orchidectomy (2). 
 
Secondly, the retroperitoneum may represent 
metastases from a  testicular primary which has 
regressed, the so called “Burnt-Out” phenomenon. 
Here, clinical and ultrasonography of the testis will be 
normal. An orchidectomy or biopsy, if performed, or 
may demonstrate areas of scarring as the primary 
tumour undergoes necrosis (2). 
 
Daugaard et al (1987) in his series of 15 EGGCT 
patients, found evidence of testicular intraepithelial 
neoplasia in 42% and carcinoma in situ in 53% of 
patients (3). All 15 patients were without clinical 
signs of a testicular tumour. In addition, 3 of these 
patients had small areas of invasive tumour growth. 
He concluded that germ-cell tumours can only be 
diagnosed as extragonadal in origin if testicular 
biopsy shows no malignant features or scarring.  In a 
separate review of 14 patients with apparent EGGCT 
who underwent orchidectomy after chemotherapy, 
71% had histological evidence of a testicular primary 
(20% teratoma, 80% focal necrosis or fibrosis). This 
was especially true if their retroperitoneal metastases 
were only unilateral, which corresponds to an 
ipsilateral testicular primary (4). 
 
Metachronous testicular malignancies do occur. In 
one series of 635 patients with apparent EGGCT, the 
rate of metachronous lesions was 4.1% with a 
cumulative risk 10 years after diagnosis being 14.2%. 
This was seen in patients with non-seminomatous 
retroperitoneal EGGCT (5). 
 
There are reports of the development of testicular 
recurrence as high as 31%, even after systemic 
response to primary chemotherapy (5). Leibovitch et 
al (1996) in a retrospective analysis of the 
orchiectomy specimens of 160 patients with 
metastatic non-seminomatous germ cell tumors who 
underwent delayed orchidectomy and retroperitoneal 
lymph node dissection post chemotherapy revealed 
necrosis or scar in 70 (43.7%), pure teratoma in 50 
(31.2%) and persistent germ cell cancer in 40 (25%). 
They concluded a need for delayed orchiectomy even 
after a partial of complete response to systemic 
chemotherapy (6.)  This phenomenon may be 
explained by the existence of blood testis barriers and 
tumor heterogeneity. Our patient underwent 4 cycles 
of chemotherapy with no evidence of residual tumour 
based on imaging of the abdomen and normalization 
of the alpha-feto protein on follow up.  
Based on the evidence so far however, he was advised 
for either a testicular biopsy rule out presence of an 
occult primary or a burnt out testicular lesion. If such 
Fig 1: CT abdomen of left para-aortic mass 
(arrow). 
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a lesion was present, then an orchidectomy would 
follow. This would help prevent the occurrence of a 
delayed testicular recurrence in the near future. 
Additionally, current evidence points that the best 
chance of detecting a positive finding in a testis is if 
the retroperitoneal mass was unilateral, as it was in 
our patient. However our patient refused any surgical 
intervention. There has been no local or distant 
recurrence past one year. He is now on three monthly 
testicular examination, ultrasound examination and 
alpha-feto protein levels.  As there are no standard 
protocols available for follow up, a reasonable 
surveillance protocol would be to follow up 3 
monthly for the first 2 years and then once a year for 
as long as ten years. The patient should also be 
advised to perform a self testicular examination 
regularly and consult the attending surgeon 
immediately if any abnormality is detected. 
 
Conclusion 
 
There will always be an on-going debate regarding 
the true existence of an extra-gonadal germ cell 
tumour. Current evidence from testicular biopsies and 
orchidectomies for extra-gonadal germ cell tumour 
reveal a 40-50% change of detecting a primary 
testicular lesion, therefore prompting physicians to 
advocate testicular biopsy all cases (3). In patients 
who elect not to, they should be counselled regarding 
the presence of harbouring a clinically occult tumour 
and the possibility of a testicular recurrence despite 
systemic chemotherapy. In such a situation, an active 
surveillance protocol comprising of testicular 
examination, ultra-sonography and check of tumour 
marker levels are necessary. The patient should also 
be followed up for a minimum of ten years.  
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